Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Asenapine, Olanzapine Effective in Patients With Bipolar 1 Disorder: Presented at WCBP - (DGDispatch)
    FDA: Boxed Warning Required for Varenicline, Buproprion Due to Risk of Suicidal Behaviour - (DGNews)
    Quetiapine Monotherapy Shows Potential in Post-Traumatic Stress Disorder: Presented at WCBP - (DGDispatch)
    Olanzapine Effective for Bipolar Disorder in Naturalistic Setting: Presented at WCBP - (DGDispatch)
    Study Suggests Irritability Should Be Considered When Diagnosing Bipolar Disorder in Children - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
      A Guide to Advances in Pain Management: A Synopsis of Roundtable Discussions
      Recognizing and Managing Psychotic and Mood Disorders in Primary Care
      Challenges of the Comorbid Patient: Evaluating Common Comorbidities in Adults and Children/Adolescents and Treatment Considerations
      Mixed States: Practical Application of Evidence, Guidelines, and Clinical Judgment
      Hypomania: The Clinical Reality of Diagnosing Adult and Child/Adolescent Patients

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Female Sexual Dysfunction as a Comorbid Illness
        11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
        Comorbidity of Asperger's Syndrome and Bipolar Disorder
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Atomoxetine Appears Beneficial for Patients with Mixed ADHD and Depressive/Anxiety Disorders: Presented at AACAP

        By Jerry Ingram

        MIAMI BEACH, FL -- October 21, 2003 -- Atomoxetine may prove to be effective for treatment of pediatric patients with ADHD and depressive/anxiety disorders, according to research presented here on October 18th at the 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry.

        "In our study we compared atomoxetine with placebo to atomoxetine with fluoxetine and what we saw was no significant differences between the two groups in terms of reduction of depressive symptoms or reduction of anxiety symptoms, suggesting that atomoxetine has the potential to address both the ADHD as well as depressive/anxiety symptoms," said Christopher Kratochvil, MD, co-author of the study, Lilly Research Laboratories, Indianapolis, Indiana.

        Researchers enrolled patients with comorbid ADHD and affective or anxiety symptoms. They randomized 46 patients to treatment with atomoxetine plus placebo and 127 to atomoxetine with fluoxetine. The 8-week study was double blind, placebo controlled, with 1:3 ratio of randomization.

        To assess the efficacy of treatment, investigators utilized the Investigator-rated ADHD Rating Scale-IV (ADHD RS), which is based on parental reports, the Children's Depression Rating Scale-Revised (CDRS-R), the Children's Depression Inventory (CDI), Multidimensional Anxiety Scale for Children (MASC) and the Clinician's Global Impression of Severity (CGI-S).

        There was an overall trend towards greater improvement in the atomoxetine/fluoxetine (A/F) group versus the atomoxetine (A) group. ADHD RS scores were 20.5 with atomoxetine and 24.0 with combination treatment (P=0.101); CDRS scores were 17.6 and 20.4 (P=0.32), MASC scores were 11.3 and 13.4 (P=0.489); CDI scores were 5.4 and 8.8 (P=0.043); and CGI-S scores were 1.9 and 2.3 (P=0.065).

        Dr. Kratochvil and his team concluded that atomoxetine may be helpful in treating patents with mixed ADHD and depressive/anxiety disorders.


        [Study title: Atomoxetine for Comorbid ADHD and Affective Symptoms. Abstract E29]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send